Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 2:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: zilucoplan Clear all
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy

NCT04025632
View directory record Official record
Conditions
Immune Mediated Necrotizing Myopathy
Interventions
zilucoplan, Placebo
Drug · Other
Lead sponsor
Ra Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
14
States / cities
Los Angeles, California • Orange, California • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 12, 2026, 2:40 AM EDT
Completed Phase 3 Interventional Results available

Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

NCT04115293
View directory record Official record
Conditions
Myasthenia Gravis, Generalized
Interventions
zilucoplan (RA101495), Placebo
Drug
Lead sponsor
Ra Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
37
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Sep 12, 2026, 2:40 AM EDT
Completed Phase 3 Interventional Results available

Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

NCT04590586
View directory record Official record
Conditions
COVID-19
Interventions
Standard of care, Apremilast, Apremilast placebo, Lanadelumab, Lanadelumab placebo, Zilucoplan, Zilucoplan placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
21
States / cities
Anniston, Alabama • Bakersfield, California • Chula Vista, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Sep 12, 2026, 2:40 AM EDT
Completed Phase 3 Interventional

Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis

NCT04225871
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
zilucoplan (RA101495)
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
33
States / cities
Mobile, Alabama • Phoenix, Arizona • Irvine, California + 29 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 12, 2026, 2:40 AM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen A Zilucoplan

NCT04436497
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Zilucoplan, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 12, 2026, 2:40 AM EDT
Completed Phase 3 Interventional Results available

An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors

NCT05514873
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
zilucoplan (RA101495)
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Scottsdale, Arizona • Los Angeles, California • Rancho Mirage, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Sep 12, 2026, 2:40 AM EDT
Recruiting Phase 3 Interventional

Zilucoplan for Severe gMG Exacerbations

NCT07215949
View directory record Official record
Conditions
Generalized Myasthenia Gravis (gMG)
Interventions
Zilucoplan®
Drug
Lead sponsor
Miriam Freimer
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Tampa, Florida • Kansas City, Kansas • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 12, 2026, 2:40 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab

NCT03030183
View directory record Official record
Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
Zilucoplan (RA101495)
Drug
Lead sponsor
Ra Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Duarte, California • Los Angeles, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 12, 2026, 2:40 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

NCT06055959
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Zilucoplan
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
12 Years to 17 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Flower Mound, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 12, 2026, 2:40 AM EDT
Terminated Phase 2 Interventional Results available

Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study

NCT03225287
View directory record Official record
Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
Zilucoplan (RA101495)
Drug
Lead sponsor
Ra Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
2
States / cities
Los Angeles, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced Sep 12, 2026, 2:40 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safe and Effective Use of a Zilucoplan Auto-injector by Study Participants With Generalized Myasthenia Gravis

NCT06471361
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
Zilucoplan
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
7
States / cities
New Haven, Connecticut • Tampa, Florida • Columbia, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 12, 2026, 2:40 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women

NCT06961747
View directory record Official record
Conditions
Healthy Participants
Interventions
Zilucoplan
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 12, 2026, 2:40 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

HEALEY ALS Platform Trial - Master Protocol

NCT04297683
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Zilucoplan, Verdiperstat, CNM-Au8, Pridopidine, SLS-005 Trehalose, ABBV-CLS-7262, DNL343, NUZ-001
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
81
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 12, 2026, 2:40 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis

NCT03315130
View directory record Official record
Conditions
Generalized Myasthenia Gravis
Interventions
zilucoplan (RA101495), Placebo
Drug
Lead sponsor
Ra Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
26
States / cities
Mobile, Alabama • Carlsbad, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 12, 2026, 2:40 AM EDT